An essential reason for the delay in drug development for children is the difficulty in conducting clinical trials in children. This thesis systematically analyzes the dilemma of children’s clinical trials from informed consent and operation implementation

and discusses the countermeasures from two aspects of extrapolation of research data and comprehensive post-market evaluation besides children’s drug clinical trials.